Computational characterization of cancer molecular profiles derived using next generation sequencing

Wspolczesna Onkologia

Volumn 1A, Issue , 2015, Pages A78-A91

  Oleksiewicz, Urszula ^a,b   Tomczak, Katarzyna ^a,b,c   Woropaj, Jakub ^d   Markowska, Monika ^e   Stȩpniak, Piotr ^e   Shah, Parantu K ^f  

^a GREATER POLAND CANCER CENTRE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d POZNA UNIVERSITY OF ECONOMICS AND BUSINESS   (Poland)

^e Transition Technologies SA   (Poland)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Next generation sequencing

Indexed keywords

TRANSCRIPTOME;

ALTERNATIVE RNA SPLICING; CANCER GENETICS; COMPUTER PROGRAM; COPY NUMBER VARIATION; DATA PROCESSING; GENE EXPRESSION; GENE FUSION; HUMAN; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SOMATIC MUTATION; TRANSCRIPTOMICS;

EID: 84981283772     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.47137     Document Type: Review

References (133)

1. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
2. Ju YS, Alexandrov LB, Gerstung M, et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. Elife 2014; 3.
3. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-8.
4. Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113-20.
5. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science 2011; 331: 1553-58.
6. Network TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
7. Network TCGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-25.
8. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
9. Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer 2014 [Epub].
10. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237-51.
11. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
12. Nagayama A, Hayashida T, Jinno H, et al. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis. J Natl Cancer Inst 2014; 106.
13. Network TCGA. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-9.
14. Network TCGA. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-50.
15. Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-7.
16. Grant GM, Fortney A, Gorreta F, et al. Microarrays in cancer research. Anticancer Res 2004; 24: 441-8.
17. Metzker ML. Sequencing technologies-the next generation. Nat Rev Genet 2010; 11: 31-46.
18. Zhao S, Fung-Leung WP, Bittner A, Ngo K, Liu X. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS One 2014; 9: e78644.
19. Irizarry RA, Warren D, Spencer F, et al. Multiple-laboratory comparison of microarray platforms. Nat Methods 2005; 2: 345-50.
20. Kerr MK, Churchill GA. Experimental design for gene expression microarrays. Biostatistics 2001; 2: 183-201.
21. Quackenbush J. Microarray data normalization and transformation. Nat Genet 2002; 32 Suppl: 496-501.
22. Yang YH, Speed T. Design issues for cDNA microarray experiments. Nat Rev Genet 2002; 3: 579-88.
23. Alkodsi A, Louhimo R, Hautaniemi S. Comparative analysis of methods for identifying somatic copy number alterations from deep sequencing data. Brief Bioinform 2014 (Epub).
24. Flicek P, Birney E. Sense from sequence reads: methods for alignment and assembly. Nat Meth 2009; 6: S6-12.
25. Medvedev P, Stanciu M, Brudno M. Computational methods for discovering structural variation with next-generation sequencing. Nat Meth 2009; 6: S13-20.
26. Nielsen R, Paul JS, Albrechtsen A, Song YS. Genotype and SNP calling from next-generation sequencing data. Nat Rev Genet 2011; 12: 443-51.
27. Pepke S, Wold B, Mortazavi A. Computation for ChIP-seq and RNAseq studies. Nat Meth 2009; 6: S22-32.
28. Soneson C, Delorenzi M. A comparison of methods for differential expression analysis of RNA-seq data. BMC Bioinformatics 2013; 14: 91.
29. Del Fabbro C, Scalabrin S, Morgante M, Giorgi FM. An extensive evaluation of read trimming effects on illumina NGS data analysis. PLoS ONE 2013; 8: e85024.
30. Shang J, Zhu F, Vongsangnak W, Tang Y, Zhang W, Shen B. Evaluation and comparison of multiple aligners for next-generation sequencing data analysis. Biomed Res Int 2014; 2014: 309650.
31. Soneson C, Delorenzi M. A comparison of methods for differential expression analysis of RNA-seq data. BMC Bioinformatics 2013; 14: 91.
32. Horner DS, Pavesi G, Castrignanò T, De Meo PD, Liuni S, Sammeth M, Picardi E, Pesole G. Bioinformatics approaches for genomics and post genomics applications of next-generation sequencing. Brief Bioinform 2010; 11: 181-97.
33. Chen C, Khaleel SS, Huang H, Wu CH. Software for pre-processing Illumina next-generation sequencing short read sequences. Source Code Biol Med 2014; 9: 8.
34. Miller JR, Koren S, Sutton G. Assembly algorithms for next-generation sequencing data. Genomics 2010; 95: 315-327.
35. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10: R25.
36. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-111.
37. Luo G-Z, Yang W, Ma Y-K, Wang X-J. ISRNA: an integrative online toolkit for short reads from high-throughput sequencing data. Bioinformatics 2014; 30: 434-6.
38. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol 2010; 11: R106.
39. Auer PL DR. A two-stage poisson model for testing RNA-seq data. Stat Appl Gen Mol Biol 2011; 10: Article 26.
40. Di Y SD, Cumbie JS, Chang JH. The NBP negative binomial model for assessing differential gene expression from RNA-seq. Stat Appl Genet Mol Biol 2011; 10: Article 24.
41. Hardcastle TJ, Kelly KA. baySeq: empirical Bayesian methods for identifying differential expression in sequence count data. BMC Bioinformatics 2010; 11: 422.
42. Robinson MD, Smyth GK. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. Biostatistics 2008; 9: 321-32.
43. Zhou YH, Xia K, Wright FA. A powerful and flexible approach to the analysis of RNA sequence count data. Bioinformatics 2011; 27: 2672-8.
44. Bullard J, Purdom E, Hansen K, Dudoit S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinformatics 2010; 11: 94.
45. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 2008; 18: 1509-17.
46. Denoeud F, Kapranov P, Ucla C, et al. Prominent use of distal 5' transcription start sites and discovery of a large number of additional exons in ENCODE regions. Genome Res 2007; 17: 746-59.
47. Tress ML, Martelli PL, Frankish A, et al. The implications of alternative splicing in the ENCODE protein complement. Proc Natl Acad Sci U S A 2007; 104: 5495-500.
48. Lee JY, Yeh I, Park JY, Tian B. PolyA-DB 2: mRNA polyadenylation sites in vertebrate genes. Nucleic Acids Res 2007; 35: D165-8.
49. Peng Z, Cheng Y, Tan BC-M, et al. Comprehensive analysis of RNASeq data reveals extensive RNA editing in a human transcriptome. Nat Biotech 2012; 30: 253-60.
50. Ramaswami G, Lin W, Piskol R, Tan MH, Davis C, Li JB. Accurate identification of human Alu and non-Alu RNA editing sites. Nat Meth 2012; 9: 579-81.
51. Ramaswami G, Zhang R, Piskol R, Keegan LP, Deng P, O'Connell MA, Li JB. Identifying RNA editing sites using RNA sequencing data alone. Nat Meth 2013; 10: 128-32.
52. Gregg C, Zhang J, Weissbourd B, Luo S, Schroth GP, Haig D, Dulac C. High-resolution analysis of parent-of-origin allelic expression in the mouse brain. Science 2010; 329: 643-8.
53. Zhang R, Li X, Ramaswami G, Smith KS, Turecki G, Montgomery SB, Li JB. Quantifying RNA allelic ratios by microfluidic multiplex PCR and sequencing. Nat Methods 2014; 11: 51-4.
54. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011; 25: 1915-27.
55. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature 2012; 489: 101-8.
56. Khoury JD, Tannir NM, Williams MD, et al. Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol 2013; 87: 8916-26.
57. Tang K-W, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun 2013; 4: 2513.
58. Piskol R, Ramaswami G, Li Jin B. Reliable identification of genomic variants from RNA-Seq dData. Am J Hum Genet. 2013; 93: 641-51.
59. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-83.
60. Kim TM, Xi R, Luquette LJ, Park RW, Johnson MD, Park PJ. Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res 2013; 23: 217-27.
61. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-8.
62. Baudis M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 2007; 7: 226.
63. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184-99.
64. Döhner H, Stilgenbauer S, Benner A, et al. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. N Engl J Med 2000; 343: 1910-6.
65. Louhimo R, Lepikhova T, Monni O, Hautaniemi S. Comparative analysis of algorithms for integration of copy number and expression data. Nat Meth 2012; 9: 351-5.
66. Kallioniemi A, Kallioniemi O, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258: 818-21.
67. Mullighan CG, Downing JR. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia 2009; 23: 1209-18.
68. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-8.
69. Chiang DY, Getz G, Jaffe DB, et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Meth 2009; 6: 99-103.
70. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 207-11.
71. Bignell GR, Huang J, Greshock J, et al. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 2004; 14: 287-95.
72. Handsaker RE, Korn JM, Nemesh J, McCarroll SA. Discovery and genotyping of genome structural polymorphism by sequencing on a population scale. Nat Genet 2011; 43: 269-76.
73. Yoon S, Xuan Z, Makarov V, Ye K, Sebat J. Sensitive and accurate detection of copy number variants using read depth of coverage. Genome Res 2009; 19: 1586-92.
74. Tuzun E, Sharp AJ, Bailey JA, et al. Fine-scale structural variation of the human genome. Nat Genet 2005; 37: 727-32.
75. Campbell PJ, Stephens PJ, Pleasance ED, et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 2008; 40: 722-9.
76. Karakoc E, Alkan C, O'Roak BJ, Dennis MY, Vives L, Mark K, Rieder MJ, Nickerson DA, Eichler EE. Detection of structural variants and indels within exome data. Nat Meth 2012; 9: 176-8.
77. Fromer M, Moran JL, Chambert K, et al. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet 2012; 91: 597-607.
78. Soon WW, Hariharan M, Snyder MP. High-throughput sequencing for biology and medicine. Mol Syst Biol 2013; 9: 640.
79. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013; 339: 1546-58.
80. Wang Q, Jia P, Li F, Chen H, Ji H, Hucks D, Dahlman KB, Pao W, Zhao Z. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. Genome Med 2013; 5: 91.
81. Christoforides A, Carpten JD, Weiss GJ, Demeure MJ, Von Hoff DD, Craig DW. Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics 2013; 14: 302.
82. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
83. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-9.
84. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012; 28: 1811-7.
85. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-76.
86. Xi R LJ, Hadjipanayis A, Kim TM, Park PJ. BIC-seq: a fast algorithm for detection of copy number alterations based on high-throughput sequencing data. Genome Biol 2010; 11: O10.
87. Yang L, Luquette Lovelace J, Gehlenborg N, et al. Diverse mechanisms of somatic structural variations in human cancer genomes. Cell 153: 919-29.
88. Krumm N, Sudmant PH, Ko A, et al. Copy number variation detection and genotyping from exome sequence data. Genome Res 2012; 22: 1525-32.
89. Chen K, Wallis JW, McLellan MD, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods 2009; 6: 677-81.
90. Marx V. Cancer genomes: discerning drivers from passengers. Nat Meth 2014; 11: 375-9.
91. Merid SK, Goranskaya D, Alexeyenko A. Distinguishing between driver and passenger mutations in individual cancer genomes by network enrichment analysis. BMC Bioinformatics 2014; 15: 308.
92. Raphael BJ, Dobson JR, Oesper L, Vandin F. Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med 2014; 6: 5.
93. Dees ND, Zhang Q, Kandoth C, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res 2012; 22: 1589-98.
94. Hua X, Xu H, Yang Y, Zhu J, Liu P, Lu Y. DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. Am J Hum Genet 2013; 93: 439-51.
95. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
96. Zhang Q, Ding L, Larson DE, et al. CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data. Bioinformatics 2010; 26: 464-9.
97. van Dyk E, Reinders MJ, Wessels LF. A scale-space method for detecting recurrent DNA copy number changes with analytical false discovery rate control. Nucleic Acids Res 2013; 41: e100.
98. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073-81.
99. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-9.
100. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011; 39: e118.
101. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 2009; 69: 6660-7.
102. Ye J, Pavlicek A, Lunney EA, Rejto PA, Teng CH. Statistical method on nonrandom clustering with application to somatic mutations in cancer. BMC Bioinformatics 2010; 11: 11.
103. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63.
104. Ryslik GA, Cheng Y, Cheung KH, Modis Y, Zhao H. Utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics 2013; 14: 190.
105. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-50.
106. Wendl MC, Wallis JW, Lin L, Kandoth C, Mardis ER, Wilson RK, Ding L. PathScan: a tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics 2011; 27: 1595-602.
107. Boca SM, Kinzler KW, Velculescu VE, Vogelstein B, Parmigiani G. Patient-oriented gene set analysis for cancer mutation data. Genome Biol 2010; 11: R112.
108. Cerami E, Demir E, Schultz N, Taylor BS, Sander C. Automated network analysis identifies core pathways in glioblastoma. PLoS One 2010; 5: e8918.
109. Vandin F, Upfal E, Raphael BJ. Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol 2011; 18: 507-22.
110. Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 2012; 22: 398-406.
111. Leiserson MD, Blokh D, Sharan R, Raphael BJ. Simultaneous identification of multiple driver pathways in cancer. PLoS Comput Biol 2013; 9: e1003054.
112. Miller CA, Settle SH, Sulman EP, Aldape KD, Milosavljevic A. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. BMC Med Genomics 2011; 4: 34.
113. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277-80.
114. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-6.
115. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
116. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18: 375-7.
117. Edgren H, Murumagi A, Kangaspeska S et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol 2011; 12: R6.
118. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014; 40: 300-6.
119. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
120. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458: 97-101.
121. Zhao Q, Caballero OL, Levy S, et al. Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. Proc Natl Acad Sci U S A 2009; 106: 1886-91.
122. Wang Q, Xia J, Jia P, Pao W, Zhao Z. Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. Brief Bioinform 2013; 14: 506-19.
123. Supper J, Gugenmus C, Wollnik J, et al. Detecting and visualizing gene fusions. Methods 2013; 59: S24-8.
124. Biankin AV, Waddell N, Kassahn KS et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399-405.
125. Paweletz CP, Liotta LA, Petricoin EF, 3rd. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 2001; 57: 160-3.
126. Yadav VK, De S. An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. Brief Bioinform 2014 [Epub].
127. Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB, Huse J, Ladanyi M, Sander C. Integrative subtype discovery in glioblastoma using iCluster. PLoS One 2012; 7: e35236.
128. Yan Z, Shah PK, Amin SB, et al. Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feed-forward loops identifies regulators in human cancers. Nucleic Acids Res 2012; 40: e135.
129. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-7.
130. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-5.
131. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-4.
132. Samur MK, Yan Z, Wang X, Cao Q, Munshi NC, Li C, Shah PK. canEvolve: a web portal for integrative oncogenomics. PLoS One 2013; 8: e56228.
133. Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. Genes Dev 2011; 25: 534-55.